Myovant Sciences (NYSE: MYOV) is one of 48 publicly-traded companies in the “Biopharmaceuticals” industry, but how does it weigh in compared to its peers? We will compare Myovant Sciences to related businesses based on the strength of its risk, valuation, analyst recommendations, earnings, dividends, profitability and institutional ownership.
Insider and Institutional Ownership
79.2% of Myovant Sciences shares are held by institutional investors. Comparatively, 43.2% of shares of all “Biopharmaceuticals” companies are held by institutional investors. 2.8% of Myovant Sciences shares are held by company insiders. Comparatively, 15.4% of shares of all “Biopharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Myovant Sciences has a beta of -2.44, meaning that its stock price is 344% less volatile than the S&P 500. Comparatively, Myovant Sciences’ peers have a beta of 1.03, meaning that their average stock price is 3% more volatile than the S&P 500.
Earnings and Valuation
This table compares Myovant Sciences and its peers revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Myovant Sciences||N/A||-$83.44 million||-9.33|
|Myovant Sciences Competitors||$564.12 million||$96.17 million||40.99|
Myovant Sciences’ peers have higher revenue and earnings than Myovant Sciences. Myovant Sciences is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This table compares Myovant Sciences and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Myovant Sciences Competitors||-13,602.79%||-100.87%||-25.29%|
This is a breakdown of recent ratings for Myovant Sciences and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Myovant Sciences Competitors||137||800||1748||59||2.63|
Myovant Sciences currently has a consensus target price of $22.50, indicating a potential upside of 71.10%. As a group, “Biopharmaceuticals” companies have a potential upside of 13.28%. Given Myovant Sciences’ stronger consensus rating and higher possible upside, equities analysts plainly believe Myovant Sciences is more favorable than its peers.
About Myovant Sciences
Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland. Inhibition of GnRH receptors decreases the release of the gonadotropins, luteinizing hormone, or LH, and follicle-stimulating hormone, or FSH, thereby decreasing the down-stream production of estrogen and progesterone by the ovaries in women and testosterone by the testes in men. It is advancing relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids, endometriosis-associated pain and prostate cancer. It intends to develop its second product candidate, RVT-602, for the treatment of female infertility as part of assisted reproduction.
Receive News & Ratings for Myovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences Ltd and related companies with MarketBeat.com's FREE daily email newsletter.